No products in the cart.
Aprepitant Capsules
$1.00
Aprepitant Capsules (Kangrenping), 125mg ×1 + 80mg ×2 per box. For laboratory research use only
Description
Aprepitant Capsules Product Overview
Aprepitant (marketed under Kangrenping) is the world’s first NK1 receptor antagonist antiemetic. Manufactured by Beijing Sihuan Pharmaceutical Co., Ltd., this formulation includes one 125mg capsule and two 80mg capsules per box. Approved by China’s NMPA with drug codes H20243266/H20243265, product code 86900153001025, and barcode 6924330200289. For laboratory research use only—not indicated for clinical or human use. pmc.ncbi.nlm.nih.gov+1viwit.com+1
Product Specifications
| Attribute | Details |
|---|---|
| Product Name | Aprepitant Capsules (Kangrenping) |
| Strength | 125mg ×1 & 80mg ×2 capsules per box |
| Formulation | Oral capsule |
| Approval Numbers | H20243266 (125mg), H20243265 (80mg) |
| Product Code | 86900153001025 |
| Barcode | 6924330200289 |
| Manufacturer | Beijing Sihuan Pharmaceutical Co., Ltd. |
| Intended Use | Laboratory research only — Not for human use |
Mechanism of Action
Aprepitant is a neurokinin1 (NK1) receptor antagonist that blocks substance P receptors—key mediators of chemotherapy- and surgery-induced vomiting
Research & Usage Notes
Clinically used to prevent acute and delayed vomiting in CINV and PONV .
Widely studied in pharmacokinetic trials across ethnic groups; safe and well tolerated
The domestic Kangrenping® is China’s 5th approved generic but shows strong market performance (~¥400M/year)
Research Applications
CINV/PONV studies (in vitro PK/PD modeling)
NK?1 receptor binding or antagonist assays
Pharmacokinetic studies & metabolism
CYP3A4 interaction screening
Aprepitant Capsules Handling & Storage
Store at 20–25°C, keep in original packaging
Use standard lab PPE (gloves, mask, etc.)
Avoid ingestion or skin contact
Additional information
| Weight | 1 kg |
|---|---|
| Dimensions | 18 × 16 × 18 cm |
1 review for Aprepitant Capsules
Related products
Lenalidomide Capsules (Qipuyi) – 25mg
Lenalidomide (brand name Qipuyi) is an immunomodulatory drug (IMiD) produced by Qilu Pharmaceutical Co., Ltd. Each box contains 21 capsules of 25mg each. Approved by China's NMPA under H20193115, and product code 86904021003685 (barcodes: 6915798005257, 6915798005721). Strictly for laboratory research use only $1.00Cetuximab NO1 Injection
Cetuximab NO1 Injection, 100mg in 50mL vial, is a biosimilar developed by Sichuan Kelun Botai Biopharma, branded as Datalai®. Approved in China (NMPA S20250006), this EGFR-targeting monoclonal antibody is ideal for laboratory or analytical research in oncology $1.00Ivodazumab Injection (lvonescimab)
Ivodazumab (Yidafang) is a monoclonal antibody developed by Kangfang Pharmaceutical Co., Ltd., approved by China's NMPA (Approval No. S20240020; Drug Code: 86985204000011). Each vial contains 10ml of the injectable formulation. Strictly for laboratory research use only—not for clinical or human use.
$1.00Fulzerasib Tablets (Dupert) – 150mg
Fulzerasib (Dupert) is an orally active KRAS G12C inhibitor, conditionally approved in China for advanced non–small-cell lung cancer (NSCLC) with KRAS G12C mutation. Manufactured by CindaBio, NMPA approved under H20240035 (drug code: 86985200000015). Strictly for laboratory research use only—NOT for clinical or human consumption. $1.00
moore –
The effect is good, I will buy from you next month